Drugs and genotypes: How pharmacogenetic information could improve smoking cessation treatment

Journal of Psychopharmacology

Volumn 20, Issue 4 SUPPL., 2006, Pages 7-14

  Lee, Anna M ^a   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bupropion; CYP2A6; CYP2B6; Dopamine D2 receptor; Nicotine replacement therapy; OPRM1; Pharmacogenetics; SLC6A3; Smoking cessation

Indexed keywords

AMFEBUTAMONE; BETA ENDORPHIN; COTININE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; MECAMYLAMINE; METHOXSALEN; MU OPIATE RECEPTOR; NALOXONE; NICOTINE; NICOTINIC RECEPTOR; OPIATE RECEPTOR; VARENICLINE; VENLAFAXINE;

ABSTINENCE; ALLELE; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; GENE; GENE LOCUS; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MOLECULAR INTERACTION; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SLC6A3 GENE; SMOKING; SMOKING CESSATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG THERAPY; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; RECEPTORS, DOPAMINE D2; RECEPTORS, NICOTINIC; SMOKING CESSATION;

EID: 33750063673     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786806066039     Document Type: Review

References (79)

1. Audrain-McGovern J, Lerman C, Wileyto E P, Rodriguez D, Shields P G (2004) Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry 161: 1224-1230
2. Befort K, Filliol D, Decaillot F M, Gaveriaux-Ruff C, Hoehe M R, Kieffer B L (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276: 3130-3137
3. Beyer A, Koch T, Schroder H, Schulz S, Hollt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89: 553-560
4. Bond C, LaForge K S, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong J A, Leal S M, Tischfield J A, Kreek M J, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95: 9608-9613
5. Boyadjieva N I, Sarkar D K (1997) The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 61: PL59-66
6. Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, Minna J (2004) The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 6: 229-239
7. Coe J W, Brooks P R, Vetelino M G, Wirtz M C, Arnold E P, Huang J, Sands S B, Davis T I, Lebel L A, Fox C B, Shrikhande A, Heym J H, Schaeffer E, Rollema H, Lu Y, Mansbach R S, Chambers L K, Rovetti C C, Schulz D W, Tingley F D, O'Neill B T (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-3477
8. Damaj M I, Carroll F I, Eaton J B, Navarro H A, Blough B E, Mirza S, Lukas R J, Martin B R (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66: 675-682
9. David S P, Niaura R, Papandonatos G D, Shadel W G, Burkholder G J, Britt D M, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths S E, Walton R T (2003) Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 5: 935-942
10. De Luca V, Wong A H, Muller D J, Wong G W, Tyndale R F, Kennedy J L (2004) Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 29: 1522-1526
11. Erblich J, Lerman C, Self D W, Diaz G A, Bovbjerg D H (2004) Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenomics J 4: 102-109
12. Erblich J, Lerman C, Self D W, Diaz G A, Bovbjerg D H (2005) Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers. Mol Psychiatry 10: 407-414
13. Faucette S R, Hawke R L, Lecluyse E L, Shord S S, Yan B, Laethem R M, Lindley C M (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28: 1222-1230
14. Feng Y, Niu T, Xing H, Xu X, Chen C, Peng S, Wang L, Laird N, Xu X (2004) A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 75: 112-121
15. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo M C, Reimherr F, Wender P, Yaw J, Young D A, Breese C R, Adams C, Patterson D, Adler L E, Kruglyak L, Leonard S, Byerley W (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94: 587-592
16. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi M A, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Kamataki T (2004) Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25: 2451-2458
17. Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74: 363-396
18. Gourlay S, Forbes A, Marriner T, Kutin J, McNeil J (1994) A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther 55: 64-69
19. Gu D F, Hinks L J, Morton N E, Day I N (2000) The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 64: 383-390
20. Heath A C, Kirk K M, Meyer J M, Martin N G (1999) Genetic and social determinants of initiation and age at onset of smoking in Australian twins. Behav Genet 29: 395-407
21. Hughes J R, Shiffman S, Callas P, Zhang J (2003) A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 12: 21-27
22. Hukkanen J, Jacob P III, Benowitz N L (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57: 79-115
23. Hurt R D, Sachs D P, Glover E D, Offord K P, Johnston J A, Dale L C, Khayrallah M A, Schroeder D R, Glover P N, Sullivan C R, Croghan I T, Sullivan P M (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195-1202
24. Jacobsen L K, Staley J K, Zoghbi S S, Seibyl J P, Kosten T R, Innis R B, Gelernter J (2000) Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 157: 1700-1703
25. Johnstone E C, Yudkin P L, Hey K, Roberts S J, Welch S J, Murphy M F, Griffiths S E, Walton R T (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14: 83-90
26. Jonsson E G, Nothen M M, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall G C (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4: 290-296
27. Jorm A F, Henderson A S, Jacomb P A, Christensen H, Korten A E, Rodgers B, Tan X, Easteal S (2000) Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 96: 331-334
28. Koenigs L L, Trager W F (1998) Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 37: 10047-10061
29. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock M L, Fackenthal J D, Rogan P K, Ring B, Wrighton S A, Schuetz E G (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307: 906-922
30. Lang T, Klein K, Fischer J, Nussler A K, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger U M (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11: 399-115
31. Lerman C, Swan G E (2002) Non-replication of genetic association studies: is DAT all, folks? Nicotine Tob Res 4: 247-249
32. Lerman C, Patterson F, Berrettini W (2005a) Treating tobacco dependence: state of the science and new directions. J Clin Oncol 23: 311-323
33. Lerman C, Caporaso N E, Audrain J, Main D, Bowman E D, Lockshin B, Boyd N R, Shields P G (1999) Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18: 14-20
34. Lerman C, Shields P G, Wileyto E P, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12: 627-634
35. Lerman C, Shields P G, Wileyto E P, Audrain J, Hawk L H, Jr., Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein L H (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22: 541-548
36. Lerman C, Berrettini W, Pinto A, Patterson F, Crystal-Mansour S, Wileyto E P, Restine S L, Leonard D G, Shields P G, Epstein L H (2004a) Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl) 174: 571-577
37. Lerman C, Wileyto E P, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields P G, Kaufmann V, Redden D, Benowitz N, Berrettini W H (2004b) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4: 184-192
38. Lerman C, Jepson C, Wileyto E P, Epstein L H, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W (2005b) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31: 231-242
39. Li M D, Beuten J, Ma J Z, Payne T J, Lou X Y, Garcia V, Duenes A S, Crews K M, Elston R C (2005) Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 14: 1211-1219
40. Lueders K K, Hu S, McHugh L, Myakishev M V, Sirota L A, Hamer D H (2002) Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2). Nicotine Tob Res 4: 115-125
41. MacKay J, Eriksen M (2002) In Jeremy P, Lacey C (eds), The Tobacco Atlas. World Health Organization, Geneva. 1-128
42. McRobbie H, Lee M, Juniper Z (2005) Non-nicotine pharmacotherapies for smoking cessation. Respir Med 99: 1203-1212
43. Madden P A, Heath A C, Pedersen N L, Kaprio J, Koskenvuo M J, Martin N G (1999) The genetics of smoking persistence in men and women: a multicultural study. Behav Genet 29: 423-431
44. Maes H H, Sullivan P F, Bulik C M, Neale M C, Prescott C A, Eaves L J, Kendler K S (2004) A twin study of genetic and environmental influences in tobacco initiation, regular tobacco use and nicotine dependence. Psychol Med 34: 1251-1261
45. Malaiyandi V, Sellers E M, Tyndale R F (2005) Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77: 145-158
46. Mansvelder H D, McGehee D S (2002) Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 53: 606-617
47. Marubio L M, Gardier A M, Durier S, David D, Klink R, Arroyo-Jimenez M M, McIntosh J M, Rossi F, Champtiaux N, Zoli M, Changeux J P (2003) Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 17: 1329-1337
48. Messina E S, Tyndale R F, Sellers E M (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282: 1608-1614
49. Michelhaugh S K, Fiskerstrand C, Lovejoy E, Bannon M J, Quinn J P (2001) The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J Neurochem 79: 1033-1038
50. Miyazaki M, Yamazaki H, Takeuchi H, Saoo K, Yokohira M, Masumura K I, Nohmi T, Funae Y, Imaida K, Kamataki T (2005) Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone-induced mouse lung adenomas. Carcinogenesis 26: 1947-1955
51. Munafo M, Clark T, Johnstone E, Murphy M, Walton R (2004) The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 6: 583-597
52. Neville M J, Johnstone E C, Walton R T (2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23: 540-545
53. Picciotto M R, Zoli M, Rimondini R, Lena C, Marubio L M, Pich E M, Fuxe K, Changeux J P (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-177
54. Pohjalainen T, Rinne J O, Nagren K, Lehikoinen P, Anttila K, Syvalahti E K, Hietala J (1998) The Al allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3: 256-260
55. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers E M, Tyndale R F (2000) Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58: 747-755
56. Rose J E, Behm F M (2004) Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob Res 6: 523-532
57. Rose J E, Behm F M, Westman E C (1998) Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 6: 331-343
58. Rose J E, Behm F M, Westman E C, Levin E D, Stein R M, Ripka G V (1994) Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56: 86-99
59. Sabol S Z, Nelson M L, Fisher C, Gunzerath L, Brody C L, Hu S, Sirota L A, Marcus S E, Greenberg B D, Lucas F R, Benjamin J, Murphy D L, Hamer D H (1999) A genetic association for cigarette smoking behavior. Health Psychol 18: 7-13
60. Salas R, Fieri F, De Biasi M (2004) Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. J Neurosci 24: 10035-10039
61. Schinka J A, Town T, Abdullah L, Crawford F C, Ordorica P I, Francis E, Hughes P, Graves A B, Mortimer J A, Mullan M (2002) A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry 7: 224-228
62. Schoedel K A, Hoffmann E B, Rao Y, Sellers E M, Tyndale R F (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14: 615-626
63. Sellers E M, Kaplan H L, Tyndale R F (2000) Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68: 35-43
64. Sellers E M, Ramamoorthy Y, Zeman M V, Djordjevic M V, Tyndale R F (2003) The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone (NNK) metabolism in vivo. Nicotine Tob Res 5: 891-899
65. Shiffman S, Rolf C N, Hellebusch S J, Gorsline J, Gorodetzky C W, Chiang Y K, Schleusener D S, Di Marino M E (2002) Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction 97: 505-516
66. Silverman M A, Neale M C, Sullivan P F, Harris-Kerr C, Wormley B, Sadek H, Ma Y, Kendler K S, Straub R E (2000) Haplotypes of four novel single nucleotide polymorphisms in the nicotinic acetylcholine receptor beta2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence. Am J Med Genet 96: 646-653
67. Smith G B, Bend J R, Bedard L L, Reid K R, Petsikas D, Massey T E (2003) Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab Dispos 31: 1134-1141
68. Sullivan P F, Kendler K S (1999) The genetic epidemiology of smoking. Nicotine Tob Res 1 (Suppl. 2): S51-7; discussion S69-70
69. Swan G E, Valdes A M, Ring H Z, Khroyan T V, Jack L M, Ton C C, Curry S J, McAfee T (2005) Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 5: 21-29
70. Takeuchi H, Saoo K, Matsuda Y, Yokohira M, Yamakawa K, Zeng Y, Miyazaki M, Fujieda M, Kamataki T, Imaida K (2005) Dose dependent inhibitory effects of dietary 8-methoxypsoralen on NNK-induced lung tumorigenesis in female A/J mice. Cancer Lett
71. Tonnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel P I, Hider A, Sweet R, Townsend J (2003) A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 254: 184-192
72. Vandenbergh D J, Persico A M, Hawkins A L, Griffin C A, Li X, Jabs E W, Uhl G R (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14: 1104-1106
73. Vandenbergh D J, Bennett C J, Grant M D, Strasser A A, O'Connor R, Stauffer R L, Vogler G P, Kozlowski L T (2002) Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 4: 333-340
74. Wagena E J, Knipschild P, Zeegers M P (2005) Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 100: 317-326
75. Walters C L, Cleck J N, Kuo Y C, Blendy J A (2005) Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46: 933-943
76. Yudkin P, Munafo M, Hey K, Roberts S, Welch S, Johnstone E, Murphy M, Griffiths S, Walton R (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. Bmj 328: 989-990
77. Zhang W, Kilicarslan T, Tyndale R F, Sellers E M (2001) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29: 897-902
78. Zhang Y, Wang D, Johnson A D, Papp A C, Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280: 32618-32624
79. Zhu S, Melcer T, Sun J, Rosbrook B, Pierce J P (2000) Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 18: 305-311